Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline

ACTA MEDICA INDONESIANA · Vol. 55 No. 4 (2024)

ISSN
2338-2732, 0125-9326
Terbit
2024-01-12
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July 2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)% respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases.

Kata kunci

Jaringan kolaborasi para penulis

18 penulis · 58 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Putu Dyah WidyaningsihAfiliasi tidak diketahui2
Tutik KusmiatiAfiliasi tidak diketahui2
Johanes Nugroho Eko PutrantoAfiliasi tidak diketahui2
Budi SupraptiAfiliasi tidak diketahui2
Nadya LuthfahAfiliasi tidak diketahui2
Winariani KoesoemoprodjoAfiliasi tidak diketahui2
Aryani Prawita SariAfiliasi tidak diketahui2
Cholichul HadiAfiliasi tidak diketahui2
Ni Njoman JuliasihAfiliasi tidak diketahui2
Reny Mareta SariAfiliasi tidak diketahui2
Ilham Nur AlfianAfiliasi tidak diketahui2
Tiffany Tiara PakasiAfiliasi tidak diketahui2
Muchamad Ali SyafaatAfiliasi tidak diketahui1
Nadir NadirUniversity of Brawijaya1
Jazim HamidiUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients  at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline</dc:title>
	<dc:creator>Setyawan, Muhamad Frendy</dc:creator>
	<dc:creator>Mertaniasih, Ni Made</dc:creator>
	<dc:creator>Soedarsono, Soedarsono</dc:creator>
	<dc:subject xml:lang="en-US">drug-resistant tuberculosis</dc:subject>
	<dc:subject xml:lang="en-US">treatment regimen</dc:subject>
	<dc:subject xml:lang="en-US">bedaquiline</dc:subject>
	<dc:subject xml:lang="en-US">WHO guidelines</dc:subject>
	<dc:subject xml:lang="en-US">pulmonary tuberculosis</dc:subject>
	<dc:subject xml:lang="en-US">pulmonology</dc:subject>
	<dc:description xml:lang="en-US">Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the  MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July  2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)%  respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2024-01-12</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">A retrospective cross-sectional</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2285</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 55 No. 4 (2023): Acta Medica Indonesiana; 430</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2285/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2024 Muhamad Frendy Setyawan, Ni Made Mertaniasih, Soedarsono Soedarsono, Zakiyathun Nuha</dc:rights>
</oai_dc:dc>